Quadrant Capital Group LLC increased its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 9,242.9% in the 1st quarter, HoldingsChannel reports. The firm owned 654 shares of the company’s stock after acquiring an additional 647 shares during the period. Quadrant Capital Group LLC’s holdings in Neurocrine Biosciences were worth $56,000 at the end of the most recent reporting period.
Several other large investors have also added to or reduced their stakes in the stock. Vanguard Group Inc grew its position in shares of Neurocrine Biosciences by 2.7% during the third quarter. Vanguard Group Inc now owns 7,772,236 shares of the company’s stock worth $955,597,000 after purchasing an additional 204,065 shares in the last quarter. BB Biotech AG grew its holdings in Neurocrine Biosciences by 5.9% during the 4th quarter. BB Biotech AG now owns 3,343,090 shares of the company’s stock valued at $238,730,000 after buying an additional 185,000 shares in the last quarter. First Trust Advisors LP grew its holdings in Neurocrine Biosciences by 27.3% during the 4th quarter. First Trust Advisors LP now owns 1,299,455 shares of the company’s stock valued at $92,794,000 after buying an additional 278,598 shares in the last quarter. Geode Capital Management LLC grew its holdings in Neurocrine Biosciences by 4.2% during the 4th quarter. Geode Capital Management LLC now owns 907,292 shares of the company’s stock valued at $64,789,000 after buying an additional 36,508 shares in the last quarter. Finally, Norges Bank purchased a new position in Neurocrine Biosciences during the 4th quarter valued at approximately $61,171,000. Hedge funds and other institutional investors own 99.33% of the company’s stock.
NBIX has been the subject of several research analyst reports. ValuEngine upgraded Neurocrine Biosciences from a “hold” rating to a “buy” rating in a report on Friday, February 8th. Barclays restated a “buy” rating and set a $110.00 price target on shares of Neurocrine Biosciences in a report on Friday, March 29th. JPMorgan Chase & Co. cut Neurocrine Biosciences from an “overweight” rating to a “neutral” rating and raised their price target for the company from $97.00 to $100.00 in a report on Wednesday, January 23rd. Oppenheimer raised their price target on Neurocrine Biosciences from $105.00 to $110.00 and gave the company an “outperform” rating in a report on Wednesday, March 13th. Finally, HC Wainwright restated a “buy” rating and set a $102.00 price target on shares of Neurocrine Biosciences in a report on Tuesday, January 15th. Five analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $103.42.
Neurocrine Biosciences (NASDAQ:NBIX) last announced its earnings results on Monday, April 29th. The company reported ($1.12) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.05) by ($0.07). The company had revenue of $138.40 million during the quarter, compared to analysts’ expectations of $136.77 million. Neurocrine Biosciences had a negative return on equity of 9.14% and a negative net margin of 7.56%. Neurocrine Biosciences’s revenue for the quarter was up 94.7% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.47) EPS. As a group, research analysts forecast that Neurocrine Biosciences, Inc. will post -0.24 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: “Quadrant Capital Group LLC Buys 647 Shares of Neurocrine Biosciences, Inc. (NBIX)” was originally published by Baseball Daily News and is the property of of Baseball Daily News. If you are viewing this piece of content on another website, it was copied illegally and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.baseballdailydigest.com/news/2019/05/12/quadrant-capital-group-llc-buys-647-shares-of-neurocrine-biosciences-inc-nbix.html.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health.
Featured Article: Why do commodities matter?
Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIX).
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.